Gen-Probe Incorporated develops, manufactures, and markets nucleic acid probe-based products used for the clinical diagnosis of human diseases, and for screening donated human blood in North America and internationally. The company markets and sells its clinical diagnostic products in the United States directly and outside the United States primarily through distributors, as well as through its direct sales force, and the company also markets and sells its other products through collaborative partners. The company's blood screening products are marketed and distributed worldwide by Novartis. In addition, the company has agreements with Siemens (as assignee of Bayer Corporation), bioMérieux, Inc., or bioMérieux, and Fujirebio, Inc., through its subsidiary Rebio Gen, Inc., or Rebio Gen, to market products in various overseas markets. The company is developing NAT assays and instruments for the detection of harmful pathogens in the environment and biopharmaceutical and beverage manufacturing processes. The company has entered into collaboration agreements with GE Infrastructure Water and Process Technologies, or GEI, a unit of General Electric Company, and Millipore Corporation, or Millipore, under which the company would be primarily responsible for developing and manufacturing assays for exclusive use or sale by its collaborative partners in specified fields with in the industrial testing market. Products The company has applied its core technologies to develop multiple product lines, all of which utilize its expertise in NAT probes, sample collection and processing. The company categorizes its products into clinical diagnostic products and blood screening products. Clinical Diagnostic Products Within its clinical diagnostic product group, the company has developed products for the detection of non-viral and viral microorganisms and for the detection of markers for cancer. Clinical Diagnostic Products for the Detection of Non-Viral Microorganisms The company has developed FDA-approved amplified and non-amplified NAT assays that detect non-viral micro-organisms primarily for use in clinical diagnostics. The company's principal products for the detection of non-viral microorganisms include its non-amplified AccuProbe and PACE family of products and its amplified Mycobacterium Tuberculosis Direct Test and amplified APTIMA products. AccuProbe Products: The company's AccuProbe Culture Identification products are tools for the identification of mycobacterial, fungal and bacterial pathogens, with sensitivities and specificities approaching 100% in most cases. These products allow for the detection of target organisms from primary cultures, eliminating the additional labor of purifying secondary cultures. All AccuProbe Culture Identification assays are based on its HPA technology. As part of its AccuProbe Culture Identification product line, the company also has developed a procedure to detect GBS from broth culture. Group A Streptococcus Direct: The Group A Streptococcus Direct Test, or GASDirect assay, is a NAT assay for the direct detection of Streptococcus pyogenes in one hour from a throat swab. PACE Product Family: The company's PACE 2C offers the testing for both chlamydia infections and gonorrhea from a single patient specimen.

Autobio Diagnostics is a company mainly engaged in development, manufacture and sales of diagnostics products.

Vysis develops, commercializes and markets clinical products that provide information critical to the evaluation and management of cancer, prenatal disorders and other genetic diseases. The Company has assembled a management team experienced in developing,commercializing and marketing DNA based diagnostic products and associated genetic workstations. The Company was the first to obtain Food and Drug Administration ("FDA") clearance for a genomic product using fluorescence INSITU hybridization ("FISH"). Vysis currently markets four FDA cleared clinical products in addition to distributing over 240 research products through its direct sales operations in the United States and Europe and a worldwide distribution network covering 28 countries. It has an installed base of over 320 proprietary genetic workstations at 224 laboratories in 18 countries. The Company has a pipeline of nine clinical products under development and an expanding list of clinical product leads based upon its collaborations with leading medical research institutions, which include the University of California, San Francisco, the Mayo Clinic, St. Jude Children's Research Hospital, the University of Chicago and the Reproductive Genetics Institute.

Sansure Biotech, Inc. engages in the research, development, production, and sales of diagnostic reagents and instruments. It also provides third-party medical testing services. The company's products include viral hepatitis, genital infection & genetics, pediatric infection, respiratory infection, nucleic acid blood screening, scientific research, public health, animal disease, nucleic acid extraction, and biochemical series reagents; automatic nucleic acid detection reaction system, and point-of-care testing mobile molecular diagnostic system series instrument; and fluorescence polymerase chain reaction assay software. Sansure Biotech was founded on April 23, 2008 and is headquartered in Changsha, China.

UAB Research Foundation (doing business as UABRF), a subsidiary of The University of Alabama System, is a company headquartered in Birmingham, AL. The firm engages in identify, assess, and market commercially viable technology developed at The University of Alabama at Birmingham.

Bioyong Technology, Inc. (doing business as Beijing Yi Xinbo Chuang Biotechnology Co., Ltd.) is a Chinese private company located in Changping. The firm develops mass spectrometry technologies.

Shanghai Guoxing Medical Equipment Co., Ltd., established on 2011-06-17, Business scope includes licensed projects:Class III medical device business;Disinfectant production;food business;Production of Class III Medical Devices;Production of Class II Medical Devices.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments) General project:Wholesale of Class I Medical Devices,Wholesale of Class II Medical Devices,Retailing of Class I Medical Devices,Retailing of Class II Medical Devices,Production of Class I Medical Devices,Special Labor Protection Articles,daily mask,Production and sales of textiles,Disinfectant sales,Production of hygiene products,Sanitary Products Sales,Engaged in technology development in the field of intelligent technology,technical consulting,Technical Services,technology transfer,Big data application service,Engage in technology development in the fields of biotechnology and computer software,technical consulting,Technical Services,technology transfer,laboratory equipment,Chemical Products(Removal of hazardous chemicals,Monitor Chemicals,firecrackers,precursor chemicals,civilian explosives)promotion of,business inquiries,Engaged in the import and export of goods and technology,Nutrition and Health Consulting Services,medical consultation,The following limited branch operations:Production and sales of reagents and consumables.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Amoco Corporation is a global chemical and oil company that provides kerosene and gasoline products. The company is also engaged in the exploration and production business. The company’s products include axle grease for industrial machinery, paraffin wax for candles, and kerosene for home lighting, drive-through filling stations, and gasoline tanker trucks. Amoco Corporation was founded in 1889 by John. D. Rockefeller and is headquartered in Illinois.

Wuhan Zhongzhi Biotechnologies' main product, multiple respiratory pathogen nucleic acid detection reagents, is developed based on its own core patented technology-dual amplification technology combining T7RNA isothermal amplification and multi-biotin signal amplification. The company has built a number of molecular detection technology platforms with international leading levels, including multi-biotin signal amplification technology, dual amplification technology, nucleic acid POCT rapid detection technology, etc.

Guangdong Hybribio Biotech Co., Ltd. engages in the research, development, production, and sale of nucleic acid molecular diagnostic products in China. It also provides on-site technical training and after-sales technical service support. The company was founded by Qiao Zhong Guan on June 13, 2003 and is headquartered in Chaozhou, China.

LSI Medience Corp. engages in the clinical examination business. It also engages in the diagnostic agent and drug discovery support business. The company was founded on April 1, 2014 and is headquartered in Tokyo, Japan.

Research Corporation Technologies, Inc. provides investment related services. It operates as technology development company that typically invests in new technology platforms in life sciences, healthcare technology, biomedical, preclinical and clinical-stage therapeutics, devices, drugs, and diagnostics, medical devices, and biotech tools for gene expression and protein production with medical devices. The company was founded in 1987 and is headquartered in Tucson, AZ.

Jiangxi Yaoyang Medical Technology Co., Ltd., established on 2013-05-14, Business scope includes licensed projects:Production of Class II Medical Devices,Production of Class III Medical Devices(Items subject to approval by law,Business activities can only be carried out within the validity period of the license after being approved by the relevant department,The specific business items and license period are subject to the approval documents or licenses of relevant departments) General project:Sales of Class I Medical Devices,Production of Class I Medical Devices,Information Technology Consulting Services,Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion,Computer and Office Equipment Repair,Specialty Chemicals Sales(Free of Hazardous Chemicals),Instrument Repair,Metering technical service,Domestic trade agent,Import and export,rental service(Licensed rental services not included),Class I Medical Device Leasing,Special Equipment Repair,Feed Additive Sales,Natural science research and experimental development,R&D and application of cell technology,Instrument sales,Medical Research and Experimental Development(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Shanghai Rendu Biotechnology Co., Ltd. develops molecular diagnostic tests. It mainly focuses on RNA molecular diagnostic technology and products. The company is committed to the development and promotion of RNA based on real-time fluorescent constant temperature amplification detection technology (SAT technology for short) molecular diagnostic products. Shanghai Rendu Biotechnology was founded on June 13, 2007 and is headquartered in Shanghai, China.

Hubei Hualong Biopharmaceutical Co., Ltd., established on 2004-05-25, Business range includes tablet(Contains psychotropic substances:Estazolam Tablets),Granules,hard capsule,dry suspension,mixture,Powder,syrup,API(Valacyclovir Hydrochloride,imidazole salicylate),production of anti(suppress)Bacteria,agriculture,Planting of original Chinese herbal medicines(licorice,ephedra herb,musk,Eucommia,Magnolia except),one type,Production and sales of Class II medical devices and import and export business(Does not contain items prohibited or restricted by the country,Goods excluded);forestry planting;Medical technology research and development,transfer;Production and sales of candies;Production and sales of health food;Business Management Consulting Services;plant,Equipment rental service;Pharmaceutical Sales Consulting;Manufacturing and sales of cosmetics;disinfection products(Free of Hazardous Chemicals)production and sales of.(Involved in licensing projects,It should be operated after obtaining the permission of the relevant department)

Guangzhou Hongxiang Biomedical Technology Co., Ltd., established on 2012-11-21, Business scope includes technical services(Does not include license approval items);Research and development of biodiagnostic reagents and kits(Does not include license approval items);Biological Products Testing;Biotechnology Development Services;Biotechnology Consulting,communication service;Biotechnology Transfer Services;Research and development of biological products(Does not include licensed operations);Agricultural Science Research and Experimental Development;Forestry scientific research service;Animal Husbandry Scientific Research Services;Aquaculture scientific research service;Biomedical Technology Research;Operation of non-licensed medical devices;Wholesale of office equipment consumables;Instrument wholesale;Office Equipment Wholesale;Special Equipment Sales;commission agent;Technology Import and Export;Sales of products produced by the company(Except for projects prohibited by national laws and regulations;Products involving licensed operation need to obtain a license before they can be operated);Sales of biological diagnostic reagents and kits(Does not include license approval items);Sales of Biological Products(Does not include licensed operations);Medical supplies and equipment retail(Does not contain drugs and medical devices);Retailing of office equipment consumables;Electrical equipment retail;Animal Testing Services;Stem Cell Biotechnology Services;Biological product(No vaccine)wholesale;Preparation of cell preparations and related products;medical diagnosis,Monitoring and treatment equipment retail

Shanghai Yulon Medical Laboratory Co., Ltd., established on 2008-03-13, Business scope includes general items:Clinical Laboratory Services,Health Checkup Service,Medical Research and Experimental Development,Health Advisory,software development,Information system integration service,internet data service,Information processing and storage support services,Internet of Things Technology Services,Information Technology Consulting Services,Internet information service,Instrument sales,Experimental analysis instrument sales,Smart Instrument Sales,Optical Instrument Sales,Sales of electronic measuring instruments,drawing,Sales of computers and measuring instruments,Chemical product sales(No licensed chemical products),Specialty Chemicals Sales(Free of Hazardous Chemicals),Sales of electrical accessories,software sales.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Sino-Swed TongKang Biological Technology Inc. is engaged in the modern biological technology development and the application 'China-Sweden' joint-technology enterprise. The firm develops diagnosis reagents, prophylaxis medicines and the digitization medical equipments for medicine clinical examination, animal quarantine and prophylaxis domain. The company is founded in August 2002 and is headquartered in ShenZhen, China.

Taipu Bioscience (China) Co., Ltd., established on 2004-04-07, Business scope includes monoclonal and polyclonal antibodies,Immunohistochemical Reagents,Immunodiagnostic Reagents,Gene Diagnostic Reagents,Molecular Biology Reagents,Laboratory supporting equipment and test consumables,The third category is related to the detection of pathogenic pathogen antigen antibodies and nucleic acids,In vitro diagnostic reagents related to human genetic testing,to develop,Production,Sales and external laboratories,diagnosis;wholesale,Retailing of three types of clinical laboratory analysis instruments and in vitro diagnostic reagents,Class II medical laboratory and basic equipment,In vitro diagnostic reagents managed by medical devices,In Vitro Diagnostic Reagents Regulated by Drugs;Medical Equipment Leasing;Medical Research and Experimental Development;Import and export of various commodities and technologies(Import and export commodity catalog is not attached),Except for the goods and technologies that the state restricts the company to operate or prohibits the import and export of;Manage the export business of the company's self-produced products and the machinery and equipment needed by the company,spare parts,Import business of raw and auxiliary materials(Import and export commodity catalog is not attached),Except for the goods and technologies that the state restricts the company to operate or prohibits the import and export of;Other unlisted professional equipment repairs(Items not subject to permit approval);Other unlisted professional technical services(Items not subject to permit approval).(The above business projects do not include projects within the scope of special management measures for foreign investment access)

Tianjin Biochip Technology Co., Ltd., established on 2003-09-26, The scope of business includes the development of biotechnology products,Production,processing,Sales and related technology transfer;Bioinformatics and Biotechnology Consulting,Serve.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)